ClinicalTrials.gg
CompletedNCT04335084HELPCOVID-19Updated Nov 4, 2026Results posted

A Study of Hydroxychloroquine, Vitamin C, Vitamin D, and Zinc for the Prevention of COVID-19 Infection

A Phase 2 interventional study of Hydroxychloroquine and Vitamin C in COVID-19, Coronavirus Infection and Sars-CoV2, sponsored by ProgenaBiome. Completed at 1 site in United States. Open to participants aged 18 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-11-04.

Sponsored by ProgenaBiome · Phase 2, Interventional, and Prevention

How we know

Updated Nov 4, 2026Results postedStudy documents posted+1 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
254
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 125 studies testing hydroxychloroquine in COVID-19 — 3 open to participants now, 3 under way, 2 of them phase 3. Hydroxychloroquine · COVID-19.

Enrollment
43rd of 125
254 · median 105
Started
2020
with 117 others
Phase 2
29 of 125
1 open now
Registered
26th of 125
by date

Among the 125 studies testing hydroxychloroquine in COVID-19, this one is the 43rd largest by enrollment, is one of 118 that started in 2020, is one of 29 in phase 2, and was the 26th registered.

COVID-19

7,996 studies on the registry are indexed under COVID-19; 469 are open to participants now.

Browse COVID-19 studies →

Open to participants now

3 of the 125 studies testing hydroxychloroquine in COVID-19 are open now, in 12 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 3 open studies →

About hydroxychloroquine

Hydroxychloroquine: first FDA approval 1955 (PLAQUENIL). What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 356 COVID-19 studies recruiting now, 205 (58%) set no upper age limit and 84 (24%) stop at 75 or younger; 90 take children under 18; 135 take healthy volunteers.

This study: 18 Years and older · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 125 studies testing hydroxychloroquine in COVID-19, or all of them as a file.
02

Study summary

This is a Phase II interventional study testing whether treatment with hydroxychloroquine, Vitamin C, Vitamin D, and Zinc can prevent symptoms of COVID-19

Read the detailed description

In this study, subjects will take a regimen of hydroxychloroquine, vitamin C, vitamin D, and Zinc to test if this combination can prevent COVID-19. Treatment with hydroxychlorquine will last 1 day. Treatment with vitamin C, vitamin D, and and zinc will last 12 weeks. The study will last 12 weeks.

03

Conditions studied

  • COVID-19
  • Coronavirus Infection
  • Sars-CoV2
  • Corona Virus Infection
  • COVID
  • Coronavirus
  • Coronavirus-19
  • Coronavirus 19
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. , provided electronically via the EDC, demonstrating the subject understands the procedures required for the study and the purpose of the study
  2. Male or female patients 18 years of age or older that are considered to be high-risk individuals.

    a. High-risk individuals are defined as all health care workers in hospitals, clinics, and emergency rooms, and medical facilities.

  3. Subjects must agree to practice at least two highly effective methods of for the duration of the study This includes condoms with spermicide, oral birth control pills, contraceptive implants, intra-uterine devices, or diaphragms. At least one of these must be a barrier method. Subjects not of will be exempt (e.g. , surgically sterilized)

Exclusion criteria

Exclusion Criteria:

  1. Refusal to provide
  2. Any previous positive test for COVID-19 by RT-PCR
  3. Symptomatic for COVID-19
  4. Diarrhea prior to the start of treatment
  5. Type I or II diabetes
  6. Atherosclerotic Coronary Artery Disease
  7. Any for treatment with hydroxychloroquine including:

    1. Hypoglycemia
    2. G6PD deficiency
    3. Porphyria
    4. Anemia
    5. Neutropenia
    6. Alcoholism
    7. Myasthenia Gravis
    8. Skeletal muscle disorder
    9. Maculopathy
    10. Changes in the visual field
    11. Liver disease, with /AST > 2.5 upper limit normal and total >2.5 upper limit normal
    12. Psoriasis
    13. Any contraindicated medications found in Appendix 2
  8. Any comorbidities which, in the opinion of the investigator, constitute health risk for the subject.
  9. Vaccination for SARS-CoV-2
Terms in these criteria, in plain language(7)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Reproductive potential

Able to have children. For women this usually means from the first period until menopause, unless permanently unable to through surgery; for men, unless permanently sterile. Read who the line is about — participants, women, men, or their partners.

Criteria about it usually ask for contraception during the study and for a time after it.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

05

Study design

Phase
Phase 2
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Single group
Masking
Double (Participant, Investigator)
Enrollment
254 participants (actual)

Study arms

  • Experimental
    Medical Workers

    Medical workers who are exposed to COVID-19 and as such are at higher risk for infection.

    Drug: Hydroxychloroquine · Dietary Supplement: Vitamin C · Dietary Supplement: Vitamin D · Dietary Supplement: Zinc

  • Placebo comparator
    Placebo

    Medical workers who are exposed to COVID-19 and as such are at a higher risk for infection

    Dietary Supplement: Vitamin C · Dietary Supplement: Vitamin D · Dietary Supplement: Zinc

Interventions

06

What researchers measure

Primary outcomes

  1. Number of Participants Who Tested Negative and Positive for COVID-19

    Any symptoms of COVID-19 will be recorded in a daily diary. Symptoms (including fever measured in degrees Fahrenheit, dry cough, productive cough, difficulty speaking, wheezing, dry mouth, headache, chest tightness, difficulty with exertion, shortness of breath, sore throat, malaise, and diarrhea) will be rated as not present, mild, moderate, or severe.

    Time frame: 24 weeks

Secondary outcomes

  1. Adverse Events

    To assess the presence or absence of side effects (graded 1-5)

    Time frame: 24 weeks

07

Results

Posted Nov 4, 2026

Participant flow

Patients were recruited from the PI's medical clinic, word-of-mouth, and www.clinicaltrials.gov.

Participant flow — Overall Study
MilestoneMedical WorkersPlacebo
Started9082
Completed6864
Not completed2218
Withdrew: Withdrawal by subject156
Withdrew: Lack of efficacy712

Outcome measures

PrimaryNumber of Participants Who Tested Negative and Positive for COVID-19

Any symptoms of COVID-19 will be recorded in a daily diary. Symptoms (including fever measured in degrees Fahrenheit, dry cough, productive cough, difficulty speaking, wheezing, dry mouth, headache, chest tightness, difficulty with exertion, shortness of breath, sore throat, malaise, and diarrhea) will be rated as not present, mild, moderate, or severe.

Time frame:
24 weeks
Reported as:
Count of participants · Participants
Number of Participants Who Tested Negative and Positive for COVID-19
ParticipantsMedical WorkersPlacebo
COVID Negative8370
COVID Positive712
SecondaryAdverse Events

To assess the presence or absence of side effects (graded 1-5)

Time frame:
24 weeks
Reported as:
Number · participants
Adverse Events
participantsMedical WorkersPlacebo
AE Experienced3637
No AE5445

Adverse events

Collected over One year 11 months. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Placebo0/82 (0%)12/82 (14.6%)28/82 (34.1%)
Medical Workers0/90 (0%)7/90 (7.8%)25/90 (27.8%)
Most frequent serious events
Most frequent serious events
EventPlaceboMedical Workers
COVID +General disorders12/827/90
Most frequent other events
Most frequent other events
EventPlaceboMedical Workers
HeadacheNervous system disorders21/8213/90
FatigueGeneral disorders13/829/90
CoughRespiratory, thoracic and mediastinal disorders9/826/90
DiarrheaGastrointestinal disorders7/827/90

Baseline characteristics

Age, Continuous
Age, Continuous(years)PlaceboMedical WorkersTotal
Mean48.23 (18 to 86)47.56 (21 to 70)47.89 (18 to 86)
Sex: Female, Male
Sex: Female, Male(Participants)PlaceboMedical WorkersTotal
Female6461125
Male182947
Race (NIH/OMB)
Race (NIH/OMB)(Participants)PlaceboMedical WorkersTotal
American Indian or Alaska Native000
Asian224
Native Hawaiian or Other Pacific Islander000
Black or African American257
White7272144
More than one race000
Unknown or Not Reported61117
Previous COVID-19 Infection
Previous COVID-19 Infection(Participants)PlaceboMedical WorkersTotal
COVID Positive12719
COVID Negative7083153
08

Study locations

1 site
  • ProgenaBiome
    Ventura, California 93003, United States
09

References and documents

Publications

  • Banjanac M, Munic Kos V, Nujic K, Vrancic M, Belamaric D, Crnkovic S, Hlevnjak M, Erakovic Haber V. Anti-inflammatory mechanism of action of azithromycin in LPS-stimulated J774A.1 cells. Pharmacol Res. 2012 Oct;66(4):357-62. doi: 10.1016/j.phrs.2012.06.011. Epub 2012 Jul 3. PubMed 22766077 ↗
  • Cortegiani A, Ingoglia G, Ippolito M, Giarratano A, Einav S. A systematic review on the efficacy and safety of chloroquine for the treatment of COVID-19. J Crit Care. 2020 Jun;57:279-283. doi: 10.1016/j.jcrc.2020.03.005. Epub 2020 Mar 10. PubMed 32173110 ↗
  • Gao J, Tian Z, Yang X. Breakthrough: Chloroquine phosphate has shown apparent efficacy in treatment of COVID-19 associated pneumonia in clinical studies. Biosci Trends. 2020 Mar 16;14(1):72-73. doi: 10.5582/bst.2020.01047. Epub 2020 Feb 19. PubMed 32074550 ↗
  • Gautret P, Lagier JC, Parola P, Hoang VT, Meddeb L, Mailhe M, Doudier B, Courjon J, Giordanengo V, Vieira VE, Tissot Dupont H, Honore S, Colson P, Chabriere E, La Scola B, Rolain JM, Brouqui P, Raoult D. RETRACTED: Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial. Int J Antimicrob Agents. 2020 Jul;56(1):105949. doi: 10.1016/j.ijantimicag.2020.105949. Epub 2020 Mar 20. PubMed 32205204 ↗
  • Zhang L, Liu Y. Potential interventions for novel coronavirus in China: A systematic review. J Med Virol. 2020 May;92(5):479-490. doi: 10.1002/jmv.25707. Epub 2020 Mar 3. PubMed 32052466 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No

10

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jun 2020 to primary completion in May 2022, 23 months.

Results were first posted in Nov 2026, 4 years 5 months after primary completion.

Of 359 non-industry phase 2 interventional studies under COVID-19, half reached primary completion within 11 months of starting (the median), counting those still running; a quarter within 5 and three quarters within 18. This study's 23 months is above that.

Counting every sponsor, half of 583 studies reached it within 9 months; a quarter within 5 and three quarters within 16.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 2, 2020
First posted
Apr 6, 2020
StartActual
Jun 22, 2020
Primary completionActual
May 31, 2022
CompletionActual
Apr 11, 2024
Results first posted
Nov 4, 2026
Last update
Nov 4, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Results
Results posted
posted Nov 4, 2026
Primary outcomes
1 edited, 1 removed
What changed in the outcomes
  • ChangedBefore Prevention of COVID-19 symptoms as recorded in a daily diaryNow Number of Participants Who Tested Negative and Positive for COVID-19Time frame: 24 weeks
  • RemovedSafety as determined by presence or absence of Adverse Events and Serious Adverse EventsTime frame: 24 weeks
Nov 4, 2026
Secondary outcomes
1 added
What changed in the outcomes
  • AddedAdverse EventsTime frame: 24 weeks
Nov 4, 2026
Show all 1 update
  1. Nov 4, 2026
    Results posted
    Primary outcomes 1 edited, 1 removed
    What changed in the outcomes
    • ChangedBefore Prevention of COVID-19 symptoms as recorded in a daily diaryNow Number of Participants Who Tested Negative and Positive for COVID-19Time frame: 24 weeks
    • RemovedSafety as determined by presence or absence of Adverse Events and Serious Adverse EventsTime frame: 24 weeks
    Secondary outcomes 1 added
    What changed in the outcomes
    • AddedAdverse EventsTime frame: 24 weeks
    + 2 other changes: index terms and verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

11

Registry details

Key details

Study ID
NCT04335084
Lead sponsor
ProgenaBiome
Collaborators
DSCS CRO
Responsible party
Sponsor
First posted
Apr 6, 2020
Start date
Jun 22, 2020
Primary completion
May 31, 2022
Completion
Apr 11, 2024
Results posted
Nov 4, 2026
Last update
Nov 4, 2026

Study contacts

Sabine Hazan, MD
principal investigator · ProgenaBiome

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Hydroxychloroquine

Start the discussion